Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurogene Inc. - Common Stock (NQ:NGNE)

20.48 -0.44 (-2.08%)
Streaming Delayed Price Updated: 3:29 PM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 80,745
Open 21.43
Bid (Size) 20.23 (4)
Ask (Size) 20.51 (1)
Prev. Close 20.92
Today's Range 20.13 - 21.75
52wk Range 6.875 - 74.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday
Via Benzinga

Performance

YTD
-10.5%
-10.5%
1 Month
+15.7%
+15.7%
3 Month
+15.2%
+15.2%
6 Month
-11.7%
-11.7%
1 Year
-44.9%
-44.9%

More News

Read More
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
From Neurogene Inc.
Via Business Wire
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
From Neurogene Inc.
Via Business Wire
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
From Neurogene Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Neurogene to Participate in Upcoming Conferences
From Neurogene Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November
Via Benzinga
Exposures Fossil Fuels
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Dow Falls 100 Points; Brady Posts Upbeat Results
Via Benzinga
Topics Stocks
Exposures US Equities
Neurogene — Down 36% — Extends Losses After Side Effect Derails Its Rett Syndrome Drug
Via Investor's Business Daily
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Earnings Scheduled For November 15, 2024
Via Benzinga
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"
Via MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Dow Dips Over 200 Points; Home Depot Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities

Frequently Asked Questions

Is Neurogene Inc. - Common Stock publicly traded?
Yes, Neurogene Inc. - Common Stock is publicly traded.
What exchange does Neurogene Inc. - Common Stock trade on?
Neurogene Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neurogene Inc. - Common Stock?
The ticker symbol for Neurogene Inc. - Common Stock is NGNE on the Nasdaq Stock Market
What is the current price of Neurogene Inc. - Common Stock?
The current price of Neurogene Inc. - Common Stock is 20.48
When was Neurogene Inc. - Common Stock last traded?
The last trade of Neurogene Inc. - Common Stock was at 06/12/25 03:29 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.